COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00808522
Recruitment Status : Unknown
Verified December 2008 by New York Presbyterian Hospital.
Recruitment status was:  Recruiting
First Posted : December 16, 2008
Last Update Posted : December 16, 2008
Information provided by:
New York Presbyterian Hospital

Brief Summary:

The purpose of the study is to evaluate whether hCG will result in a decrease in breast density.

High breast density has been associated with an increased risk in breast cancer. It has also been shown that decreasing density with a drug called tamoxifen has resulted in a decreased risk in breast cancer. The investigators are looking at the effect of hCG on breast density in people who are at increased risk of developing breast cancer and our theory postulates that through the hormonal actions of hCG and tamoxifen there would be a greater reduction in breast density in patients who are treated with hCG and tamoxifen versus patients treated with tamoxifen alone. Using this data the investigators will be able to hypothesize that the treatment of hCG will result in a reduction in breast cancer rates in the population and thus make available another drug which can be used to decrease the rates of breast cancer in the population

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: hCG Phase 3

Detailed Description:

Pregnancy has been associated with a decreased risk of breast cancer. This has been reproduced in multiple studies and has been seen in multiple races.

People have been evaluating different hormones and practices associated with pregnancy to determine what factors reduce the risk of developing breast cancer in these patients. These pronounced findings have been evaluated in great detail by multiple scientists and one of the hormones which we think might be associated with a reduction in breast cancer is hCG. This statement has been backed by multiple studies which have looked at the direct effect of hCG on the growth and death of breast cancer cells in the lab and in animal models of breast cancer.

We want to determine if hCG is given to patients who are at increased risk of breast cancer will result in an accentuated decrease in breast cancer risk above and beyond the effect received by conventional breast cancer reducing protocols. Our final outcome in this study will be breast density on mammographic evaluation which is considered a marker for breast cancer. So our study will evaluate whether or not hCG will have an effect on the mammographic breast density.

After recruitment there will be two groups in our study an intervention group and non intervention group. In the intervention group patients would undergo a period of hCG injections which would last a total of 60 days and consist of 30 subcutaneous injections. The non intervention group will continue their conventional chemoprevention medication. Both groups will be followed for teo years and the images, cytology and blood samples will be sent to our labs for evaluation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women.
Study Start Date : December 2008
Estimated Primary Completion Date : December 2009
Estimated Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: hCG
Patients at high risk for breast cancer will be treated with hCG
Drug: hCG
recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
Other Name: Ovidril

No Intervention: routine care
Patients receiving routine care will be followed
Drug: hCG
recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
Other Name: Ovidril

Primary Outcome Measures :
  1. The investigators will be looking at the mammographic breast density at the start of the trial and then every 6 months for 2 years. The treatment arm will have 30 injections of Hcg over a 60 day period. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Evaluation of breast cytology and serum hormone levels at 6 monthly intervals over the course of the study. [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • On tamoxifen therapy for the treatment or prevention of breast cancer.
  • Must have at least one remaining breast.

Exclusion Criteria:

  • Pregnant or nursing.
  • No history of allergic reactions to hCG.
  • Patients who have had bilateral mastectomies.
  • Uncontrolled thyroid disease.
  • Cognitively impaired and unable to consent for the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00808522

Layout table for location information
United States, New York
New York Downtown Hospital Recruiting
New York, New York, United States, 10038
Contact: Giuseppe Del Priore, MD, MPH    212-312-5268   
Sub-Investigator: Alan S Klapper, MD         
Sub-Investigator: Steven Freidman, MD         
Sub-Investigator: Joseph Bottino, MD         
Sub-Investigator: Raffi Chalian, MD         
Sponsors and Collaborators
New York Presbyterian Hospital
Layout table for additonal information
Responsible Party: Giuseppe Del Priore, New Downtown Hospital Identifier: NCT00808522    
Other Study ID Numbers: GD-10-08
First Posted: December 16, 2008    Key Record Dates
Last Update Posted: December 16, 2008
Last Verified: December 2008
Keywords provided by New York Presbyterian Hospital:
Breast Cancer
Breast density
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases